Attached files

file filename
8-K - IMAGENETIX INC /NV/v212972_8k.htm
 
Exhibit 99.1

FOR IMMEDIATE RELEASE
Contact
Imagenetix Investor Relations
William P. Spencer
   
(858)385-2797
Chief Executive Officer
     
Imagenetix, Inc.
     
Tel: (858) 674-8455

IMAGENETIX, INC. REPORTS THIRD QUARTER 2011 RESULTS

San Diego, CA***February 25, 2011***Imagenetix, Inc. (OTCBB:IAGX) announced today results for the three and nine months ended December 31, 2010. Net sales decreased 4% for the third quarter of fiscal year 2011 to $1,696,000 from $1,765,000 for the same period of last year.   A loss of $1,202,000, $0.10 per share, was reported for the third quarter of fiscal year 2011, compared to a net loss of $294,000, $.03 per share, for the same period of the prior fiscal year.

For the nine months ended December 31, 2010, net sales increased 11% to $6,001,000 from $5,368,000 for the same period the previous fiscal year.  The company reported a  net loss of $1,736,000, $0.15 per share, compared to a net loss of $156,000, $0.01 per share, for the previous fiscal year.  The previous fiscal year included one-time before tax settlement income of $1,250,000.
 
Commenting on the results of the third quarter, Mr. William Spencer, Imagenetix Chief Executive Officer said: “The loss during the quarter was driven by our advertising and promotional campaigns.  Although quarterly sales to the mass market segment increased by 66% for the quarter, it was not enough to offset reductions in the wholesale and distribution segment sales.  This was coupled with a significant increase in advertising and sales promotions to introduce consumers to our product line that now reaches nation-wide for Celadrin softgels and BioGuard, and throughout the west for Celadrin cream.  We held many product demonstrations, offered manufacturers rebates and advertised in both print and national television media.  We recognize this to be the most effective way to increase product exposure and impact sales and product recognition over the long term. In addition, we continue to analyze strategic alliances for our array of intellectual properties as well as exploring sale of non-strategic assets.”
 
About Imagenetix
Imagenetix, based in San Diego, California, is an innovator of scientifically tested, natural-based, proprietary, bioceutical products developed to enhance human health on a global basis.  Imagenetix develops and formulates propriety over-the-counter topical creams, skincare products and nutritional supplements to be marketed globally through multiple channels of distribution.  In addition, the company develops patentable compounds for entering into licensing agreements with pharmaceutical partners.  Imagenetix is the creator of Celadrin®.  Please visit, www.celadrin.com, www.bioguardhealth.com or www.imagenetix.net.

Certain matters in this news release are forward-looking statements which are subject to risks and uncertainties that could cause actual results to vary materially from those projected.  Such risks and uncertainties include, but are not limited to, adverse fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, the size and timing of customer contracts, new or increased competition, changes in market demand, and seasonality of purchases of the company's products and services.  Additional information with respect to these and other factors, which could materially affect the company and its operations, are included in the company’s SEC filings, including its Form 10-K for the year ended March 31, 2010.

 
 

 

Imagenetix, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
(In thousands, except per share data)

   
Three Months Ended
   
Nine Months Ended
 
   
December 31,
   
December 31,
 
   
2010
   
2009
   
2010
   
2009
 
                         
Net sales
  $ 1,696     $ 1,765     $ 6,001     $ 5,368  
   Cost of sales
    1,279       878       3,460       2,973  
Gross profit
    417       887       2,541       2,395  
Gross profit percent
    24.6 %     50.3 %     42.3 %     44.6 %
                                 
Operating expenses:
                               
Selling, general and administrative
    1,816       573       3,288       1,956  
Payroll expense
    272       325       834       849  
Consulting expense
    353       434       1,106       1,009  
Operating expenses
    2,441       1,332       5,228       3,814  
                                 
Operating loss
    (2,024 )     (445 )     (2,687 )     (1,419 )
Other income
    -       3       1       6  
Settlement income
    -       -       -       1,250  
Interest expense
    (44 )     -       (158 )     (2 )
Loss before income taxes
    (2,068 )     (442 )     (2,844 )     (165 )
Income tax benefit
    (866 )     (148 )     (1,108 )     (9 )
                                 
Net loss
  $ (1,202 )   $ (294 )   $ (1,736 )   $ (156 )
                                 
Loss per share:
                               
Basic and diluted
  $ (0.10 )   $ (0.03 )   $ (0.15 )   $ (0.01 )
                                 
Weighted average common shares outstanding:
                               
Basic and diluted
    11,811       11,011       11,645       11,011  
 
 
 

 

Imagenetix, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
(In thousands)

   
December 31,
   
March 31,
 
   
2010
   
2010
 
Assets:
           
Current assets:
           
Cash and cash equivalents
  $ 171     $ 981  
Accounts receivable, net
    959       1,049  
Inventories, net
    988       1,350  
Prepaid expenses and other current assets
    282       151  
Deferred tax asset
    2,034       933  
   Total current assets
    4,434       4,464  
                 
Property and equipment, net
    67       89  
Long-term prepaid expenses
    9       18  
Other assets
    117       125  
   Total assets
  $ 4,627     $ 4,696  
                 
Liabilities and stockholders' equity:
               
Current liabilities:
               
Secured note payable to bank
  $ 1,025     $ -  
Convertible notes
    294       -  
Accounts payable
    710       997  
Accrued liabilities
    67       83  
Customer deposits
    22       25  
Contract payable
    75       86  
   Total current liabilities
    2,193       1,191  
                 
Stockholders' equity
    2,434       3,505  
                 
   Total liabilities and stockholders' equity
  $ 4,627     $ 4,696